BCM
DNTH icon

Bridgeway Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Bridgeway Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,544
Closed -$121K – 1403
2023
Q1 		$121K Sell
9,544
-3,719
-28% -$41.2K ﹤0.01% 1199
2022
Q4 		$83.8K Buy
13,263
+4,063
+44% +$71.9K ﹤0.01% 1243
2022
Q3 		$208K Hold
9,200
– – 0.01% 1134
2022
Q2 		$177K Hold
9,200
– – ﹤0.01% 1117
2022
Q1 		$427K Buy
+9,200
New +$503K 0.01% 978
2020
Q1 		– Sell
-1,893
Closed -$459K – 1300
2019
Q4 		$459K Hold
1,893
– – 0.01% 1022
2019
Q3 		$311K Sell
1,893
-1,562
-45% -$297K ﹤0.01% 1091
2019
Q2 		$815K Sell
3,455
-2,795
-45% -$691K 0.01% 802
2019
Q1 		$1.65M Buy
+6,250
New +$1.08M 0.02% 600

Other funds holding DNTH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bridgeway Capital Management's DNTH Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Dianthus Therapeutics (DNTH) in Q2 2023, closing a stake of 9,544 shares — an estimated $121K sold.

Bridgeway Capital Management first reported a position in DNTH in Q1 2019 and held it in 9 quarters. The position peaked at $1.65M in Q1 2019. 45 funds tracked by Wall St. Rank hold DNTH as of Q2 2023.

  • Bridgeway Capital Management reported no remaining Dianthus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 9,544 Dianthus Therapeutics shares in Q2 2023, an estimated $121K.
  • Bridgeway Capital Management first reported a position in Dianthus Therapeutics in Q1 2019 and held it in 9 quarters.
  • Bridgeway Capital Management's Dianthus Therapeutics position peaked at $1.65M in Q1 2019.
  • 45 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.